BTS News
PharmaLegacy Research LLC, dba. BTS Research Announces Expansion of their Headquarters & In Vitro Labs in their New San Diego Facility
PharmaLegacy Research LLC, dba. BTS Research Announces Expansion of their Headquarters & In Vitro Labs in their New San Diego Facility San Diego, CA February 1, 2025 San Diego, California — BTS Research, a leading provider of in vitro and in vivo preclinical drug development services, announces the expansion of its San Diego operations. The…
Read MoreBTS Research Earns Full AAALAC Accreditation Renewal
BTS Research Earns Full AAALAC Accreditation Renewal Continued Commitment to Excellence in Laboratory Animal Care San Diego, California — BTS Research a PharmaLegacy company is pleased to announce that the company has successfully renewed its FULL ACCREDITATION from the AAALAC International Council on Accreditation, recognizing its unwavering dedication to the highest standards in laboratory animal…
Read MoreBTS Research Successfully Completes USDA Inspection with Zero Findings
BTS Research Successfully Completes USDA Inspection with Zero Findings San Diego, CA — August 28, 2024 — BTS Research, a leading contract research organization specializing in preclinical research services, is proud to announce the successful completion of its USDA inspection with zero findings. The inspection was triggered by the recent acquisition of BTS Research by…
Read MorePharmaLegacy acquires preclinical CRO BTS Research,
PharmaLegacy acquires preclinical CRO BTS Research PharmaLegacy acquires preclinical CRO BTS Research, strengthening its preclinical services and expanding laboratory operations into North America PharmaLegacy Laboratories, a provider of in vitro and in vivo preclinical drug development services, has acquired BTS Research, a San Diego-based preclinical contract research organization (CRO). As a reputable CRO providing preclinical…
Read MoreBTS Research Addresses FDA Warning Letter Satisfactorily
BTS Research Addresses FDA Warning Letter Satisfactorily From the desk of the President & CEO, April 1st, 2024 BTS is very pleased to have received a satisfactory completion of the findings the FDA had issued a warning letter on October 20th 2023. The findings were originally noted during their June 27th 2022 audit, which centered around…
Read MoreBTS Research Completes Corrections of FDA 483 Observations
BTS Research Completes Corrections of FDA 483 Observations From the desk of the President & CEO On July 8, 2022, U.S. Food and Drug Administration (FDA) Investigator concluded an inspection of the BTS Research facilities located in San Diego, CA and issued Inspectional Observations on the form FDA-483 that triggered a Warning Letter issued on…
Read More